Hepatitis C - Pipeline Review, H1 2017

Description: Hepatitis C - Pipeline Review, H1 2017

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hepatitis C - Pipeline Review, H1 2017, provides an overview of the Hepatitis C (Infectious Disease) pipeline landscape.

Hepatitis C is a contagious viral infection affecting the liver. It may spread on contact with infected blood. It may be a mild condition or may extend over a longer span of time leading to various complications. The characteristic symptoms include abdominal pain, fatigue, fever, jaundice, loss of appetite, nausea and vomiting. The predisposing factors of hepatitis C include dialysis, organ transplant and blood transfusion. Offspring of an infected mother also has high chances of contracting the disease. Hepatitis C can be controlled with the help of medications or a transplant at an advanced stage.

Report Highlights:

Pharmaceutical and Healthcare latest pipeline guide Hepatitis C - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hepatitis C (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hepatitis C (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Hepatitis C and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 13, 23, 15, 1, 52, 45 and 4 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 3, 1, 9 and 23 molecules, respectively.

Hepatitis C (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hepatitis C (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Hepatitis C (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hepatitis C (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hepatitis C (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hepatitis C (Infectious Disease).
Reasons to Purchase:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hepatitis C (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hepatitis C (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction
Hepatitis C - Overview
Hepatitis C - Therapeutics Development
Hepatitis C - Therapeutics Assessment
Hepatitis C - Companies Involved in Therapeutics Development
Hepatitis C - Drug Profiles
Hepatitis C - Dormant Projects
Hepatitis C - Discontinued Products
Hepatitis C - Product Development Milestones
Appendix

List of Tables:
Number of Products under Development for Hepatitis C, H1
Number of Products under Development by Companies, H1
Number of Products under Development by Companies, H1 2017 (Contd..1), H1
Number of Products under Development by Companies, H1 2017 (Contd..2), H1
Number of Products under Development by Companies, H1 2017 (Contd..3), H1
Number of Products under Development by Companies, H1 2017 (Contd..4), H1
Number of Products under Development by Universities/Institutes, H1
Number of Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
Products under Development by Companies, H1
Products under Development by Companies, H1 2017 (Contd..1), H1
Products under Development by Companies, H1 2017 (Contd..2), H1
Products under Development by Companies, H1 2017 (Contd..3), H1
Products under Development by Companies, H1 2017 (Contd..4), H1
Products under Development by Companies, H1 2017 (Contd..5), H1
Products under Development by Companies, H1 2017 (Contd..6), H1
Products under Development by Companies, H1 2017 (Contd..7), H1
Products under Development by Companies, H1 2017 (Contd..8), H1
Products under Development by Universities/Institutes, H1
Products under Development by Universities/Institutes, H1 2017 (Contd..1), H1
Number of Products by Stage and Target, H1
Number of Products by Stage and Target, H1 2017 (Contd..1), H1
Number of Products by Stage and Mechanism of Action, H1
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1
Number of Products by Stage and Route of Administration, H1
Number of Products by Stage and Molecule Type, H1
Hepatitis C - Pipeline by 3-V Biosciences Inc, H1
Hepatitis C - Pipeline by AbbVie Inc, H1
Hepatitis C - Pipeline by AIMM Therapeutics BV, H1
Hepatitis C - Pipeline by Akshaya Bio Inc, H1
Hepatitis C - Pipeline by Amarillo Biosciences Inc, H1
Hepatitis C - Pipeline by Amarna Therapeutics BV, H1
Hepatitis C - Pipeline by ARA Healthcare Pvt Ltd, H1
Hepatitis C - Pipeline by Aviragen Therapeutics Inc, H1
Hepatitis C - Pipeline by Beijing Kawin Technology Share-Holding Co Ltd, H1
Hepatitis C - Pipeline by Beta Pharma Inc, H1
Hepatitis C - Pipeline by Biocad, H1
Hepatitis C - Pipeline by Bioteest Pharmaceuticals Corp, H1
Hepatitis C - Pipeline by Biotest Ltd, H1
Hepatitis C - Pipeline by Boehringer Ingelheim GmbH, H1
Hepatitis C - Pipeline by Bolder Biotechnology Inc, H1
Hepatitis C - Pipeline by Bristol-Myers Squibb Company, H1
Hepatitis C - Pipeline by Cocrysal Pharma Inc, H1
Hepatitis C - Pipeline by Conatus Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by ContraVir Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by DEKK-TEC Inc, H1
Hepatitis C - Pipeline by Delpor Inc, H1
Hepatitis C - Pipeline by F. Hoffmann-La Roche Ltd, H1
Hepatitis C - Pipeline by Formune SL, H1
Hepatitis C - Pipeline by Genecode AS, H1
Hepatitis C - Pipeline by GeneCure LLC, H1
Hepatitis C - Pipeline by Gilead Sciences Inc, H1
Hepatitis C - Pipeline by GinkgoPharma Co Ltd, H1
Hepatitis C - Pipeline by GlaxoSmithKline Plc, H1
Hepatitis C - Pipeline by HanAll Biopharma Co Ltd, H1
Hepatitis C - Pipeline by ImmunoBiology Ltd, H1
Hepatitis C - Pipeline by Immunoclin Corp, H1
Hepatitis C - Pipeline by Immunootope Inc, H1
Hepatitis C - Pipeline by Inovio Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by Integrated BioTherapeutics Inc, H1
Hepatitis C - Pipeline by JN-International Medical Corp, H1
Hepatitis C - Pipeline by Johnson & Johnson, H1
Hepatitis C - Pipeline by Karyopharm Therapeutics Inc, H1
Hepatitis C - Pipeline by Kineta Inc, H1
Hepatitis C - Pipeline by Ligand Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by Medivir AB, H1
Hepatitis C - Pipeline by Merck & Co Inc, H1
Hepatitis C - Pipeline by Microbio Co Ltd, H1
Hepatitis C - Pipeline by Microbiotix Inc, H1
Hepatitis C - Pipeline by MultiCell Technologies Inc, H1
Hepatitis C - Pipeline by NeuroVive Pharmaceutical AB, H1
Hepatitis C - Pipeline by Novalex Therapeutics Inc, H1
Hepatitis C - Pipeline by Novartis AG, H1
Hepatitis C - Pipeline by NovaTarg Therapeutics Inc, H1
Hepatitis C - Pipeline by Ono Pharmaceutical Co Ltd, H1
Hepatitis C - Pipeline by Pfenex Inc, H1
Hepatitis C - Pipeline by Pfizer Inc, H1
Hepatitis C - Pipeline by PharmaEssentia Corp, H1
Hepatitis C - Pipeline by Presidio Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by Profectus BioSciences Inc, H1
Hepatitis C - Pipeline by Replicor Inc, H1
Hepatitis C - Pipeline by Rodos BioTarget GmbH, H1
Hepatitis C - Pipeline by Solon Eiendom ASA, H1
Hepatitis C - Pipeline by SomaGenics Inc, H1
Hepatitis C - Pipeline by Sorrento Therapeutics Inc, H1
Hepatitis C - Pipeline by Sudershan Biotech Ltd, H1
Hepatitis C - Pipeline by TaiGen Biotechnology Co Ltd, H1
Hepatitis C - Pipeline by TaiwanJ Pharmaceuticals Co Ltd, H1
Hepatitis C - Pipeline by Therapure Biopharma Inc, H1
Hepatitis C - Pipeline by Theravectys SA, H1
Hepatitis C - Pipeline by THEVAX Genetics Vaccine USA Inc, H1
Hepatitis C - Pipeline by Vakzine Projekt Management GmbH, H1
Hepatitis C - Pipeline by Vertex Pharmaceuticals Inc, H1
Hepatitis C - Pipeline by WhanIn Pharmaceutical Co Ltd, H1
Hepatitis C - Pipeline by Zylacta Corp, H1
Hepatitis C - Dormant Projects, H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..1), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..2), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..3), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..4), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..5), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..6), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..7), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..8), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..9), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..10), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..11), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..12), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..13), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..14), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..15), H1
Hepatitis C - Dormant Projects, H1 2017 (Contd..16), H1
Hepatitis C - Discontinued Products, H1
Hepatitis C - Discontinued Products, H1 2017 (Contd..1), H1
Hepatitis C - Discontinued Products, H1 2017 (Contd..2), H1
Hepatitis C - Discontinued Products, H1 2017 (Contd..3), H1
Hepatitis C - Discontinued Products, H1 2017 (Contd..4), H1

List of Figures:
Number of Products under Development for Hepatitis C, H1
Number of Products under Development by Companies, H1
Number of Products under Development by Universities/Institutes, H1
Number of Products by Top 10 Targets, H1
Number of Products by Stage and Top 10 Targets, H1
Number of Products by Top 10 Mechanism of Actions, H1
Number of Products by Stage and Top 10 Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Top 10 Molecule Types, H1
Number of Products by Stage and Top 10 Molecule Types, H1

Ordering:
Order Online - http://www.researchandmarkets.com/reports/4228086/
Order by Fax - using the form below
Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Hepatitis C - Pipeline Review, H1 2017
Web Address: http://www.researchandmarkets.com/reports/4228086/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td>Single User:</td>
<td>USD 2000</td>
</tr>
<tr>
<td></td>
<td>Site License:</td>
<td>USD 4000</td>
</tr>
<tr>
<td></td>
<td>Enterprisewide:</td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:

You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:

Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ______________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World